Is Terumo Corporation profitable in 2026?

Yes. Terumo posted record FY2025 (ended March 31, 2026) operating profit of ¥176.3 billion and adjusted operating profit of ¥219.4 billion on revenue of ¥1,131.9 billion, its fifth consecutive year of record sales, reported May 20, 2026.

Could AI replace Terumo's medical device business?

No. Terumo's core revenue comes from physical implanted and procedural hardware (catheters, coils, apheresis systems) that AI software cannot substitute. AI appears only as a distributed feature, like the AutocathFFR cardiac diagnostic tool launched in Japan in October 2025.

Is Terumo doing layoffs in 2026?

No layoff evidence found. Terumo's headcount has grown through acquisitions, adding roughly 200 employees when it completed the ~$1.5 billion OrganOx acquisition in October 2025, and the company is actively hiring for AI and engineering roles at Terumo BCT in 2026.

Who owns Terumo Corporation?

Terumo is an independent public company with no parent, listed on the Tokyo Stock Exchange Prime Market under ticker 4543 and included in the Nikkei 225. It has no controlling shareholder and funds growth through operations plus debt, including a $500 million bond issued April 30, 2026.

Who are Terumo's biggest competitors?

Terumo competes against much larger medtech giants including Medtronic, Johnson & Johnson, and Abbott across cardiovascular and interventional device categories. Terumo remains a long-established segment leader in areas like transradial catheters, apheresis, and neurovascular coils despite the size gap.

Did Terumo acquire OrganOx?

Yes. Terumo completed its acquisition of University of Oxford spinout OrganOx for approximately $1.5 billion on October 31, 2025, entering the organ preservation and transplant device market; the unit was later renamed Terumo Organ Technologies.

Biotech tools companies · Japan

Terumo Corporation

terumo.com ↗

Japanese medtech maker of cardiovascular devices, blood management systems and infusion pumps used in hospitals worldwide.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: FY2027 Q1 results showing post-GS 2026 strategy reset and RelayPro recall fallout

The call

Terumo keeps setting sales records on hardware AI cannot copy, while a stent-graft recall and litigation, not software, are what investors are watching.

Terumo is a 105-year-old Japanese company that makes medical devices like stents, catheters, and blood bags sold in over 160 countries. It's very hard to replace because it has decades of doctor trust, regulatory approvals from agencies like the FDA, and manufacturing systems that meet strict safety standards, while AI cannot substitute for physical devices that go inside patients. The real threat is not competition but lawsuits from a recall of thoracic stent-grafts that began in June 2026, which could drag on earnings and hurt shareholder returns over the next year or two.

Why

AI pressure: None apparent. AI helps Terumo run trial data and manufacturing analytics but cannot replace physical stents, catheters or blood-collection hardware. Could AI do the core job? Unlikely.

Bigger players: Medtronic, Boston Scientific, Becton Dickinson. Bigger rivals compete hard in cardiovascular and infusion devices, but none has displaced Terumo's hospital contracts or share. Could a giant copy it? No, they are blocked.

What protects it. Regulatory approvals across 160+ countries, ISO 13485 quality systems, and decades of hospital purchasing relationships that are slow to switch away from.

What would change this call

Regulatory action or expanded litigation tied to the RelayPro stent-graft recall over the next 6-12 months. Would show whether the recall stays a contained device issue or becomes a broader quality-system problem.
FY2027 results (around August 2026) for Neuro and organ-transplant (OrganOx) growth. Would show whether new growth engines are stalling versus continuing their recent momentum.
Outcome of ethylene-oxide litigation and Puerto Rico class action against Terumo BCT's Lakewood facility. Would show whether legal liabilities are escalating into a larger financial drag.

Key numbers

FY2025 revenue ¥1,131.9B, +9% YoY (2026-05-20)
Fifth consecutive year of record sales (2026-05-20)
Stock down ~27% over the year despite record results (2026-05-15)

Named risks

RelayPro thoracic stent-graft recall linked to deaths could escalate into broader regulatory action. Severity: high
Ongoing ethylene oxide litigation at Terumo BCT's Lakewood, Colorado facility. Severity: medium
US tariff exposure reducing profit margins despite record revenue. Severity: medium
Stock price fell ~27% over the prior year to May 2026 despite record financial results. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Medtronic	contesting	Structural rivalry in cardiovascular/interventional devices, both scaling in FY2025-2026
Abbott	contesting	Competes across vascular access and catheter segments as of 2026
Boston Scientific	contesting	Overlaps in interventional and neurovascular device categories, 2026
Fresenius	contesting	Rival in blood/apheresis technologies via Terumo BCT segment, 2026

Questions people ask

Is Terumo Corporation profitable in 2026?: Yes. Terumo posted record FY2025 (ended March 31, 2026) operating profit of ¥176.3 billion and adjusted operating profit of ¥219.4 billion on revenue of ¥1,131.9 billion, its fifth consecutive year of record sales, reported May 20, 2026.
Could AI replace Terumo's medical device business?: No. Terumo's core revenue comes from physical implanted and procedural hardware (catheters, coils, apheresis systems) that AI software cannot substitute. AI appears only as a distributed feature, like the AutocathFFR cardiac diagnostic tool launched in Japan in October 2025.
Is Terumo doing layoffs in 2026?: No layoff evidence found. Terumo's headcount has grown through acquisitions, adding roughly 200 employees when it completed the ~$1.5 billion OrganOx acquisition in October 2025, and the company is actively hiring for AI and engineering roles at Terumo BCT in 2026.
Who owns Terumo Corporation?: Terumo is an independent public company with no parent, listed on the Tokyo Stock Exchange Prime Market under ticker 4543 and included in the Nikkei 225. It has no controlling shareholder and funds growth through operations plus debt, including a $500 million bond issued April 30, 2026.
Who are Terumo's biggest competitors?: Terumo competes against much larger medtech giants including Medtronic, Johnson & Johnson, and Abbott across cardiovascular and interventional device categories. Terumo remains a long-established segment leader in areas like transradial catheters, apheresis, and neurovascular coils despite the size gap.
Did Terumo acquire OrganOx?: Yes. Terumo completed its acquisition of University of Oxford spinout OrganOx for approximately $1.5 billion on October 31, 2025, entering the organ preservation and transplant device market; the unit was later renamed Terumo Organ Technologies.

Timeline

2026-07-01Voluntary global recall of RelayPro thoracic stent-graft, ~7,000 units, 43 countries, linked to deaths
2026-05-20FY2025 results: record revenue ¥1,131.9B, fifth consecutive record year, operating profit ¥176.3B
2026-05-15Q4 FY2025 earnings call; stock down ~27% over prior year despite record results
2026-02-139-month FY2026 revenue ¥831.6B, +7.7% YoY; tariff impact cited at ¥7.0B
2025-10-31Completed OrganOx acquisition for ~$1.5B, forming Terumo Organ Technologies
2025-06-17Signed MedHub-AI distribution deal for AutocathFFR AI cardiac diagnostic in Japan
2024-10-23Terumo Europe deployed SAP BTP with AI for EMEA order processing automation
2024-09MicroVention rebranded as Terumo Neuro
1921-09-17Founded in Tokyo as Red Line Thermometer Corporation

Head to head

Nipro Corporation vs Terumo Corporation

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE